ZOETIS INC
ZTSNYSETrading Snapshot
- Day Range
- $77.03 โ $78.56
- 52-Week Range
- $68.77 โ $146.11
- Volume (shares)
- 2,617,652
- Avg Volume (shares)
- โ
- Shares Outstanding
- 413.2M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $9.47B
- Last Q Revenue
- $2.47B
- P/E Ratio
- 12.8
- P/S Ratio
- 3.4x
- EPS (TTM)
- $6.26
- Dividend Yield
- 2.69%
- Dilution (1yr)
- โ2.8%
ZOETIS INC
ZTSAbout ZOETIS INC
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Latest News & Updates

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
The stocks listed here yield up to 5.8%.

Which Pharmaceutical ETF Is the Better Buy: iSharesโ Domestic IHE or VanEckโs Global PPH?
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Zoetis (ZTS) closed at $81.03, marking a -1.18% move from the previous day.

ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.

Zoetis Receives FDA Approval for Conveniaยฎ RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.